WO2015047064A1 - Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus - Google Patents
Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus Download PDFInfo
- Publication number
- WO2015047064A1 WO2015047064A1 PCT/LV2013/000010 LV2013000010W WO2015047064A1 WO 2015047064 A1 WO2015047064 A1 WO 2015047064A1 LV 2013000010 W LV2013000010 W LV 2013000010W WO 2015047064 A1 WO2015047064 A1 WO 2015047064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- jerusalem artichoke
- lactobacillus reuteri
- pediococcus pentosaceus
- piglets
- group
- Prior art date
Links
- 240000008892 Helianthus tuberosus Species 0.000 title claims abstract description 21
- 235000003230 Helianthus tuberosus Nutrition 0.000 title claims abstract description 21
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 15
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 14
- 241000191996 Pediococcus pentosaceus Species 0.000 title claims abstract description 13
- 239000003674 animal food additive Substances 0.000 title claims abstract description 10
- 230000003115 biocidal effect Effects 0.000 title claims description 4
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000005911 diet Nutrition 0.000 claims abstract description 7
- 230000037213 diet Effects 0.000 claims abstract description 7
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 5
- 230000037396 body weight Effects 0.000 abstract description 15
- 239000006041 probiotic Substances 0.000 abstract description 12
- 235000018291 probiotics Nutrition 0.000 abstract description 12
- 241000282887 Suidae Species 0.000 abstract description 10
- 229920001202 Inulin Polymers 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract description 5
- 229940029339 inulin Drugs 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 4
- 244000144972 livestock Species 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 244000000010 microbial pathogen Species 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 12
- 235000013406 prebiotics Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000588921 Enterobacteriaceae Species 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 230000003640 procarcinogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008427 tissue turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a feed additive for use as a substitute for antibiotics, which contains powder from Jerusalem artichoke tubers (with 45% inulin) and probiotics ⁇ Lactobacillus reuteri and Pediococcus pentosaceus).
- prebiotics and/or prebiotics as feed additives may constitute an alternative to chemical therapy.
- Prebiotics are non-digestible feed ingredients that favourably affect the host by stimulating the growth and activity of specific bacteria groups mostly in the colon (Maxwell et al., 2004).
- the dominant prebiotics are fructo- oligosaccharide products (FOS, oligofructose, inulin).
- FOS fructo- oligosaccharide products
- inulin main component of Jerusalem artichoke
- Prebiotics are presumed to act by binding and removing pathogens from the intestinal tract and stimulating the immune system (Spring et al., 2000).
- probiotics include: regulation of intestinal microbial homeostasis, stabilization of the gastrointestinal barrier function (Salminen et al., 1996), expression of bacteriocins (Mazmanian et al., 2008), enzymatic activity inducing absorption and nutrition (Hooper et al., 2002; Timmerman et al., 2005), immunomodulatory effects (Salzman et al., 2003), facilitating the elimination of pathogens (Heyman & Menard, 2002), inhibition of procarcinogenic enzymes and interference with the ability of pathogens to colonize and infect the mucosa (Gill, 2003). Lactobacillus, Enter ococcus, Bacillus and Saccharomyces are actually the most used probiotics in livestock and poultry farming (Gaggia et al., 2010).
- Lactic acid bacteria are the predominant microbes that can enhance host immunity and increase resistance to disease. Probiotics act mostly in the upper compartments of the gastrointestinal tract; while prebiotics are supposed to be used as substrates for potentially beneficial bacteria in the hind gut of monogastric animals (Nemcova et al., 1999).
- association of a specific prebiotic and probiotic may have a synergetically positive effect on intestinal microflora
- the present invention provides feed additives for weaning piglets, which contain Lactobacillus reuteri (0.5 g/day/piglet), Pediococcus pentosaceus (0.5 g/day/piglet) and 3% of Jerusalem artichoke powder from the diet.
- abovementioned additives provide the possibility to produce the healthy livestock, to decrease the amount of pathogenic microorganisms in guts, to increase of body weight of pigs and to improve the feed conversion.
- the experiment was conducted at the commercial pig farms in Lithuania.
- the experimental design was conducted in randomized selection of 120 weaning piglets at 28 days of age, with five feeding trials and two replications.
- Prebiotics and/or probiotics were administered once a day for 5 weaks.
- the experimental diets can be seen in Table 1.
- the basal diet without antibiotics was formulated to meet the nutrient requirements suggested by manufacturer.
- Powders from Jerusalem artichoke tubers containing 45% of inulin
- Lactobacillus reuteri dose lxl 0 9 CFU/g
- Pediococcus pentosaceus dose lxl 0 9 CFU/g
- Powder of Jerusalem artichoke is made from cultivated plants in Lithuania.
- fecal samples were collected from the rectum at the beginning (1 th day), at 21 th day of the experiment (21 th day) and at the end of the experiment (35 th day).
- the sections of approximately 2.0 cm were aseptically removed from the jejunum and colon of slaughtered pigs, fixed in 10% formaldehyde solution at least 48 h and were stained with haematoxylin and eosin (HE) and immunohistochemically.
- HE haematoxylin and eosin
- Feeding of additives containing probiotics and prebiotics have an positive effect on increase of body weight of weaning piglets between 30 and 50 days of age.
- Highest body weight at 50 days of age showed animals from L3JA group, who receive basal diet, Lactobacillus reuteri (1 g/day/piglet) and 3% of Jerusalem artichoke powder from the diet (+7,1 % compared to the control group (BD)).
- Feed consumption per animal rearing accounting period an average of the control animals was 26.40 kg. Added prebiotic and probiotic supplements contributed to food intake. Despite the fact that food consumption was higher in the experimental groups, animals showed a better feed efficiency, hence better feed conversion rates.
- Pathogenic macroorganism E.coli 0157 was found at the closing stage of the trial in 3JA group piglets, but Salmonella enteritidis - only in control group of above mentioned stage. In the course of trial, Campylobacter coli was not found in any group of piglets.
- the morphology of the small intestine differed between the supplement-fed weaning pigs and the controls. More histopathological changes were seen ir 3JA pigs and pigs having received LP5JA. In 3JA group, a distinct degeneration process up to crypts, moderate inflammation process and plasmocytes were seen, but in LP5JA group - branching of the apical surface of villi, moderate degeneration and mitosis of enterocytes were observed. Villi had broken tip areas with large holes and surfaces free of microvilli as compared with control animals.
- BD2 B-defensins 2
- the present invention provides an antibiotic free feed additives for weaning piglets, which contain Lactobacillus reuteri, Pediococcus pentosaceus and Jerusalem artichoke powder.
- abovementioned additives provide the possibility to produce the healthy livestock, to decrease the amount of pathogenic microorganisms in guts, to increase of body weight of pigs and to improve the feed conversion.
- Substantial scope of the present invention will be defined by the appended claims.
Abstract
The present invention relates to a feed additive for use as a substitute for antibiotics, which contains powder from Jerusalem
artichoke tubers (with 45% inulin) and probiotics (Lactobacillus reuteri and Pediococcus pentosaceus). The present invention provides feed additives for weaning piglets, which contain Lactobacillus reuteri (0.5 g/day/piglet), Pediococcus
pentosaceus (0.5 g/day/piglet) and 3% of Jerusalem artichoke powder from the total diet dose. According to the present invention, abovementioned additives provide the possibility to produce the healthy livestock, to decrease the amount of pathogenic microorganisms in guts, to increase of body weight of pigs and to improve the feed conversion.
Description
ANTIBIOTIC FREE FEED ADDITIVE FOR PIGLETS FROM JERUSALEM ARTICHOKE, LACTOBACILLUS REUTERI AND PEDIOCOCCUS
PENTOSACEUS
FIELD OF THE INVENTION
The present invention relates to a feed additive for use as a substitute for antibiotics, which contains powder from Jerusalem artichoke tubers (with 45% inulin) and probiotics {Lactobacillus reuteri and Pediococcus pentosaceus).
BACKGROUND OF THE INVENTION
In commercial pig production, the most stress factors are related to weaning and post-weaning (PW) periods, what can negatively disturb the immune function and the equilibrium of intestinal microbiota (Modesto et al., 2009), to cause increased susceptibility to gut disorders (Gaggia et al., 2010) and negatively to affect growth performance of animals.
It has been suggested that- use prebiotics and/or prebiotics as feed additives may constitute an alternative to chemical therapy. Prebiotics are non-digestible feed ingredients that favourably affect the host by stimulating the growth and activity of specific bacteria groups mostly in the colon (Maxwell et al., 2004). The dominant prebiotics are fructo- oligosaccharide products (FOS, oligofructose, inulin). Established, that main component of Jerusalem artichoke is inulin, which is composed of polysaccharides and accounts for more than 50% of Jerusalem artichoke. Prebiotics are presumed to act by binding and removing pathogens from the intestinal tract and stimulating the immune system (Spring et al., 2000).
The favourable modes of action of probiotics include: regulation of intestinal microbial homeostasis, stabilization of the gastrointestinal
barrier function (Salminen et al., 1996), expression of bacteriocins (Mazmanian et al., 2008), enzymatic activity inducing absorption and nutrition (Hooper et al., 2002; Timmerman et al., 2005), immunomodulatory effects (Salzman et al., 2003), facilitating the elimination of pathogens (Heyman & Menard, 2002), inhibition of procarcinogenic enzymes and interference with the ability of pathogens to colonize and infect the mucosa (Gill, 2003). Lactobacillus, Enter ococcus, Bacillus and Saccharomyces are actually the most used probiotics in livestock and poultry farming (Gaggia et al., 2010).
Lactic acid bacteria are the predominant microbes that can enhance host immunity and increase resistance to disease. Probiotics act mostly in the upper compartments of the gastrointestinal tract; while prebiotics are supposed to be used as substrates for potentially beneficial bacteria in the hind gut of monogastric animals (Nemcova et al., 1999).
Accordingly, the association of a specific prebiotic and probiotic (for example, Jerusalem artichoke and probiotics {Lactobacillus reuteri and Pediococcus pentosaceus)) may have a synergetically positive effect on intestinal microflora
SUMMARY OF INVENTION
The present invention provides feed additives for weaning piglets, which contain Lactobacillus reuteri (0.5 g/day/piglet), Pediococcus pentosaceus (0.5 g/day/piglet) and 3% of Jerusalem artichoke powder from the diet. According to the present invention, abovementioned additives provide the possibility to produce the healthy livestock, to decrease the amount of pathogenic microorganisms in guts, to increase of body weight of pigs and to improve the feed conversion.
DETAILED DESCRIPTION OF THE INVENTION
The experiment was conducted at the commercial pig farms in Latvia. The experimental design was conducted in randomized selection of 120 weaning piglets at 28 days of age, with five feeding trials and two replications.
Prebiotics and/or probiotics were administered once a day for 5 weaks. The experimental diets can be seen in Table 1.
Table 1
Feeding trials of weaning piglets
The basal diet without antibiotics was formulated to meet the nutrient requirements suggested by manufacturer. Powders from Jerusalem artichoke tubers (containing 45% of inulin), Lactobacillus reuteri (dose lxl 09 CFU/g) and Pediococcus pentosaceus (dose lxl 09
CFU/g) are commercially available. Powder of Jerusalem artichoke is made from cultivated plants in Latvia.
For the evaluation of microbiological parameters, fecal samples were collected from the rectum at the beginning (1th day), at 21th day of the experiment (21th day) and at the end of the experiment (35th day).
The sections of approximately 2.0 cm were aseptically removed from the jejunum and colon of slaughtered pigs, fixed in 10% formaldehyde solution at least 48 h and were stained with haematoxylin and eosin (HE) and immunohistochemically.
Results
Starting of the experiment with 30 days old weaning piglets, the mean body weight in control group was 9,02 kg, but within experimental groups from 8,95 to 9,06 kg (Table 2.). Between the average body weight of piglets showed no significant differences (p>0.05). Significant differences (p<0.05) in body weight between the groups we found in groups of 65 days old piglets.
Table 2.
The average body weight of pigs within trial, kg
% towards
the control +7.1 +0.6 + 1,9 +3.4 0.0 group
Body
weight 65
26.15* 22.91* 23,11 * 26.85* 22.28 days of
ages, kg
% towards
the control +17.3 +2.8 +3,7 +20.5 0 group
* p<0.05
Feeding of additives containing probiotics and prebiotics have an positive effect on increase of body weight of weaning piglets between 30 and 50 days of age. Highest body weight at 50 days of age showed animals from L3JA group, who receive basal diet, Lactobacillus reuteri (1 g/day/piglet) and 3% of Jerusalem artichoke powder from the diet (+7,1 % compared to the control group (BD)). Whereas, at 65 days of age compared to the control group, on 20,5% highest body weight showed animals from LP3JA group, who receive basal diet, Lactobacillus reuteri (0.5 g/day/piglet), Pediococcus pentosaceus (0.5 g/day/piglet) and 3% of Jerusalem artichoke powder from the diet. Animals from other experimental groups also showed highest body weight in comparison with control group (BD) - L3JA group - + 17,3 %, 3JA group - + 2,8 %, LP5JA group - +3,7 %
In determining the daily live weight increase during the period from 30 days old to 65 days of age, we found that among the groups was
significant difference (p <0.05). In the group of control animals (BD) average daily body weight gain was 0.379 kg, in L3JA group - 0,489 kg, 3JA group - 0,396 kg, LP5JA group - 0.404 kg, but in LP3JA group - 0,51 1 kg.
Consequently, the LP3JA group animals compared to the control group showed 25.83% higher daily body weight gain (Table 3.)
Table 3.
Influence of additives of Jerusalem artichoke powder and probiotics to average daily body weight gain, kg
* p<0.05
Feed consumption per animal rearing accounting period, an average of the control animals was 26.40 kg. Added prebiotic and probiotic supplements contributed to food intake. Despite the fact that food consumption was higher in the experimental groups, animals showed a better feed efficiency, hence better feed conversion rates.
They were in the L3JA group 12.5%, in the 3JA group 2.0%), in the LP5JA group 0.5% and in the LP3JA group 13% lower compared to the control group (BD). So, we can conclude, that using feed additives, containing L.reuteri, P.pentosaceus and Jerusalem artichoke powder
decrease food consumption for production of 1 kg of body weight (Table 4)·
Table 4.
Influnce of Jerusalem artichoke powder, Lactobacillus reuteri and Pediococcus pentosaceus feed additeves to conversion of feed
Significant impact on the gut microbiota were found only in case of the synergistic effect of Jerusalem artichoke and probiotics. The results have shown that such combination could reduce levels of infection, as indicated by reduction of enteric (Enterobacteriaceae and E.coli) pathogens in fecal samples compared with the control group. In trial piglets (see Table 5) fed with LP5JA and LP3JA supplements, LAB level after 35 days of intake significantly (P<0.05) increased (13.7% and 10.7%, respectively) in comparision with the level at trial 1th day. In control group LAB level was significantly (P<0.05) lower than in other groups.
Table 5
Presence of microorganisms in fecal contents (logio CFU/g) by plate counts
NF - not found
L - Lactobacillus reuteri
P - Pediococcus pentosaceus
JA - Jerusalem artichoke powder
BD - basal diet
LAB - Lactic- Acid Bacteria
With regard to mean levels of Enterobacteriaceae and E.coli in samples analysed, there were not essential viable differences observed among trial pigs with the exception of animals fed LP5JA supplement. In this group, the amount of microorganisms of genera Enterobacteriaceae at the end of trial were by 8% decreased, but E.coli - by 1 1% decreased. Increase by 2% of Enterobacteriaceae and E.coli levels were seen only in control group.
Pathogenic macroorganism E.coli 0157 was found at the closing stage of the trial in 3JA group piglets, but Salmonella enteritidis - only in control group of above mentioned stage. In the course of trial, Campylobacter coli was not found in any group of piglets.
The morphology of the small intestine differed between the supplement-fed weaning pigs and the controls. More histopathological changes were seen ir 3JA pigs and pigs having received LP5JA. In 3JA group, a distinct degeneration process up to crypts, moderate inflammation process and plasmocytes were seen, but in LP5JA group - branching of the apical surface of villi, moderate degeneration and mitosis of enterocytes were observed. Villi had broken tip areas with large holes and surfaces free of microvilli as compared with control animals.
Our investigation indicated that B-defensins 2 (BD2) expression in jejunum and colon segments were incresed in control and 3JA groups that indicated an increasing amount of intestinal bacteria compared with other experimental pigs.
Hence we may conclude that diet supplementation with higher ration of Jerusalem artichoke powder, cause severe alterations in the morphology of jejunal villi and is associated with higher tissue turnover.
INDUSTRIAL APPLICABILITY
The present invention provides an antibiotic free feed additives for weaning piglets, which contain Lactobacillus reuteri, Pediococcus pentosaceus and Jerusalem artichoke powder. According to the present invention, abovementioned additives provide the possibility to produce the healthy livestock, to decrease the amount of pathogenic microorganisms in guts, to increase of body weight of pigs and to improve the feed conversion. Substantial scope of the present invention will be defined by the appended claims.
Claims
THE CLAIMS
An antibiotic free feed additives for weaning piglets, which contain Lactobacillus reuteri (0.5 g/day/piglet), Pediococcus pentosaceus (0.5 g/day/piglet) and 3% of Jerusalem artichoke powder from the total diet dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/LV2013/000010 WO2015047064A1 (en) | 2013-09-26 | 2013-09-26 | Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/LV2013/000010 WO2015047064A1 (en) | 2013-09-26 | 2013-09-26 | Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015047064A1 true WO2015047064A1 (en) | 2015-04-02 |
Family
ID=49328603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/LV2013/000010 WO2015047064A1 (en) | 2013-09-26 | 2013-09-26 | Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015047064A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118843A1 (en) | 2017-12-14 | 2019-06-20 | Pure Cultures, Inc. | Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals |
| CN111657402A (en) * | 2020-06-30 | 2020-09-15 | 武汉合缘绿色生物股份有限公司 | Feed additive for regulating intestinal function of pigs and preparation method thereof |
| CN114916611A (en) * | 2022-07-20 | 2022-08-19 | 山东益得来生物科技有限公司 | Jerusalem artichoke probiotic agent for promoting gastrointestinal health of fattening sheep |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247582A1 (en) * | 2002-10-11 | 2004-12-09 | Johann Binder | Feed additive and/or drinking water additive for domestic animals |
| US20100080783A1 (en) * | 2004-11-22 | 2010-04-01 | Watson James B | Microbial feed additive |
| WO2011060474A1 (en) * | 2009-11-20 | 2011-05-26 | Erber Aktiengesellschaft | Method for producing a feed additive and feed additive |
-
2013
- 2013-09-26 WO PCT/LV2013/000010 patent/WO2015047064A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247582A1 (en) * | 2002-10-11 | 2004-12-09 | Johann Binder | Feed additive and/or drinking water additive for domestic animals |
| US20100080783A1 (en) * | 2004-11-22 | 2010-04-01 | Watson James B | Microbial feed additive |
| WO2011060474A1 (en) * | 2009-11-20 | 2011-05-26 | Erber Aktiengesellschaft | Method for producing a feed additive and feed additive |
Non-Patent Citations (5)
| Title |
|---|
| BENGMARK S ET AL: "IMMUNONUTRITION: ROLE OF BIOSURFACTANTS, FIBER, AND PROBIOTIC BACTERIA", NUTRITION, ELSEVIER INC, US, vol. 14, no. 7/08, 1 January 1998 (1998-01-01), pages 585 - 594, XP001172824, ISSN: 0899-9007, DOI: 10.1016/S0899-9007(98)00030-6 * |
| GAGGIA F ET AL: "Probiotics and prebiotics in animal feeding for safe food production", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, ELSEVIER BV, NL, vol. 141, 31 July 2010 (2010-07-31), pages S15 - S28, XP027229267, ISSN: 0168-1605, [retrieved on 20100310] * |
| MEYER P D ET AL: "THE IMMUNE EFFECTS OF INULIN IN VITRO AND IN VIVO", AGRO-INDUSTRI HI-TECH, TEKNOSCIENCE, MILAN, IT, vol. 11, no. 6, 1 January 2000 (2000-01-01), pages 18 - 20, XP008026714, ISSN: 1120-6012 * |
| P. G. CASEY ET AL: "A Five-Strain Probiotic Combination Reduces Pathogen Shedding and Alleviates Disease Signs in Pigs Challenged with Salmonella enterica Serovar Typhimurium", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 6, 19 January 2007 (2007-01-19), pages 1858 - 1863, XP055039540, ISSN: 0099-2240, DOI: 10.1128/AEM.01840-06 * |
| SCHLEY P D ET AL: "THE IMMUNE-ENHANCING EFFECTS OF DIETARY FIBRES AND PREBIOTICS", BRITISH JOURNAL OF NUTRITION, CAMBRIDGE UNIV. PRESS, UK, vol. 87, no. Suppl. 02, 1 January 2002 (2002-01-01), pages S221 - S230, XP008026712, ISSN: 0007-1145, DOI: 10.1079/BJNBJN/2002541 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118843A1 (en) | 2017-12-14 | 2019-06-20 | Pure Cultures, Inc. | Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals |
| EP3723513A4 (en) * | 2017-12-14 | 2021-07-21 | Pure Cultures 2020, Inc. | Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals |
| CN111657402A (en) * | 2020-06-30 | 2020-09-15 | 武汉合缘绿色生物股份有限公司 | Feed additive for regulating intestinal function of pigs and preparation method thereof |
| CN114916611A (en) * | 2022-07-20 | 2022-08-19 | 山东益得来生物科技有限公司 | Jerusalem artichoke probiotic agent for promoting gastrointestinal health of fattening sheep |
| CN114916611B (en) * | 2022-07-20 | 2022-10-18 | 山东益得来生物科技有限公司 | Jerusalem artichoke probiotic agent for promoting gastrointestinal health of fattening sheep |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6106211B2 (en) | How to use Bacillus subtilis strains to improve animal health | |
| Adil et al. | Impact and manipulation of gut microflora in poultry: a review | |
| JP6012111B2 (en) | Animal feed additives | |
| Laurencio | Probiotic effect of Lactobacillus salivarius C 65 on productive and health indicators of lactating piglets | |
| Cholis et al. | Feeding microparticle protein diet combined with Lactobacillus sp. on existence of intestinal bacteria and growth of broiler chickens. | |
| Mudgal et al. | Effect of probiotic supplementation on growth performance of pre-ruminant buffalo (Bubalus bubalis) calves | |
| Al-Kassi et al. | Comparative study between single organic acid effect and synergistic organic acid effect on broiler performance | |
| WO2015047064A1 (en) | Antibiotic free feed additive for piglets from jerusalem artichoke, lactobacillus reuteri and pediococcus pentosaceus | |
| Widiastuti et al. | Dietary supplementation of butyric acid, probiotic Bacillus subtilis or their combination on weight gain, internal organ weight and carcass traits of the Indonesian indigenous crossbred chickens | |
| Londero et al. | Effect of an aspergillus meal prebiotic on salmonella infection in turkeys and broiler chickens | |
| CN114982874A (en) | Feed additive for improving intestinal health of broiler chickens and application thereof | |
| Suryanarayana et al. | Interactive effect of prebiotic (oligofructose) and probiotic (saccharomyces) feed additives on nutrient utilization, growth, feed conversion, and faecal microbiota population in pigs. | |
| JP2001008636A (en) | Feed composition for preventing infectious disease | |
| Hedayati et al. | Combination effect of probiotic and organic acids on blood biochemistry and immunity parameters of broilers | |
| Kumar et al. | Significance of probiotics as feed additives in livestock and poultry nutrition | |
| Ali et al. | The Effect of Using Organic Acid as an Alternative to Antibiotics Drugs on Productive and Physiological Per-formance of Broilers Ross–308 | |
| Karimi | Effect of probiotics (direct-fed microbials) in poultry production: a comprehensive review | |
| Dhiab | Effect of dried kefir milk on the productive performance of the brown Lohmann laying hens | |
| Konosonoka et al. | Feeding technology impact on broiler productivity and intestinal tract microflora | |
| Roul et al. | Effect of pro-and pre-biotic supplementation on growth and immune status of broilers during summer | |
| Shirisha et al. | Effect of a graded levels of probiotic feed supplementation on the performance in commercial broiler chicken | |
| Al-Saadi et al. | PRODUCTIVE RESPONSE TO ADDING KEFIR MILK WITH DRINKING WATER FOR THE BROILER CHICKENS EXPOSED TO THERMAL STRESS. | |
| Jannah et al. | Probiotics Addition Potential to Increase Body Weight, Feed Consumption and Feed Conversion on Pre-Layer Laying Hens | |
| Brzozowski et al. | Estimation the effectiveness of probiotics as a factor influencing the results of fattening rabbits | |
| Leary | Popular alternatives to antibiotic feed additives in monogastric production systems. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13774832 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13774832 Country of ref document: EP Kind code of ref document: A1 |